<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39317208</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-8785</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>24</Day></PubDate></JournalIssue><Title>American journal of perinatology</Title><ISOAbbreviation>Am J Perinatol</ISOAbbreviation></Journal><ArticleTitle>Maternal and Infant Morbidity and Mortality in relation to Delivery Mode in a large US Healthcare Claims Database in 2019 and 2020.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1055/a-2419-8916</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Provide contemporary data on maternal and infant outcomes after delivery to better understand risks of Cesarean section (CS).</AbstractText><AbstractText Label="STUDY DESIGN" NlmCategory="METHODS">Data for deliveries in 2019 and 2020 were obtained from a large US commercial healthcare claims database. Maternal morbidity measures included twenty Severe Maternal Morbidity (SMM) outcomes and seven additional obstetric and mental health outcomes. Infant morbidity measures included eight outcomes related to respiratory health, digestive health, atopic dermatitis, and birth trauma. Outcome prevalence was ascertained at 42 days (maternal only) and 360 days after delivery. Logistic regression was used to estimate the odds ratio (OR) and 95% confidence interval (CI) for prevalence adjusted for risk factors for delivery mode and each outcome. Analyses were conducted for 2019 and 2020 to assess the influence of the COVID-19 pandemic.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 436,991 deliveries were identified (145,061 CS; 291,930 vaginal). The prevalence of SMM was 3.3% at 42 days and 4.1% at 360 days. The covariate-adjusted odds of SMM were higher among CS than vaginal deliveries at 42 days (OR: 2.0, 95% CI: 1.9, 2.1) and 360 days (OR: 1.7, 95% CI: 1.7, 1.8). There were 226,983 infants available for analysis of outcomes at 360 days. Most adverse infant outcomes were more prevalent at 360 days among CS than vaginal deliveries, and the covariate-adjusted odds of any adverse infant outcome at 360 days were higher among CS than vaginal deliveries (OR: 1.2; 95% CI: 1.1, 1.3). Respiratory morbidity was most affected by delivery mode. Maternal and infant mortality up to 360 days was rare. Similar trends were observed in the 2019 and 2020 cohorts.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This observational study, performed using recent data obtained from a large US commercial claims database, provides contemporary evidence of risks to mothers and infants of CS relative to vaginal delivery.</AbstractText><CopyrightInformation>Thieme. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Doherty</LastName><ForeName>Brett</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-8172-3398</Identifier><AffiliationInfo><Affiliation>Safety &amp; Epidemiology, Carelon Research Inc, Wilmington, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Research, Carelon Research Inc, Wilmington, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naavaal</LastName><ForeName>Aneesh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Anthem Health Solutions, Elevance Health Inc, Indianapolis, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Chrissie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Health Economics, Elevance Health Inc, Indianapolis, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cole</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Clinical Analytics, Elevance Health Inc, Indianapolis, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MacPhee</LastName><ForeName>Leslie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Healthcare Financial Analytics, Elevance Health Inc, Indianapolis, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banning</LastName><ForeName>Leslie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Health Solutions, Elevance Health Inc, Indianapolis, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Anup</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>GA Medical Management, Elevance Health Inc, Indianapolis, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grabner</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Scientific Affairs, Carelon Research Inc, Wilmington, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stanek</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Scientific Affairs, Carelon Research Inc, Wilmington, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inglis</LastName><ForeName>Tiffany</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Carelon MBM, Elevance Health Inc, Indianapolis, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Perinatol</MedlineTA><NlmUniqueID>8405212</NlmUniqueID><ISSNLinking>0735-1631</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>BD, SL, and MG are employees of Carelon Research (a wholly owned subsidiary of Elevance Health), which conducts health services research with both internal and external funding, including a variety of private and public entities. AN, CL, KC, LM, LB, AS, ES, and TI are employees of Elevance Health. MG, ES, and LM are Elevance Health shareholders.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>4</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>4</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39317208</ArticleId><ArticleId IdType="doi">10.1055/a-2419-8916</ArticleId></ArticleIdList></PubmedData></PubmedArticle>